Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1543)	11/19/2004 1:32:16 AM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma initiated with "hold" Thursday, November 18, 2004 9:01:10 AM ET A.G. Edwards & Sons NEW YORK, November 18 (newratings.com) - Analysts at AG Edwards initiate coverage of MGI Pharma Inc (MOGN.NAS) with a "hold" rating. In a research note dated November 16 and published yesterday, the analysts mention that MGI Pharma’s revenue and earnings growth has been driven by the company’s successful acquisition and integration of the lead product, Aloxi. Since its launch in September 2003, Aloxi has been received well in the market and its 2004 sales are expected to be higher than the estimates by $150 million, the analysts add. The drug’s reimbursement advantages are, however, likely to significantly reduce in 2005, AG Edwards says.